NCT07285694Active, not recruitingPhase 1/2
AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)
An Open-label, Multicenter Phase 1/2 Study to Evaluate the Safety and Efficacy of AB-3028 in Patients With Castration Resistant Prostate Cancer (CRPC)
Source: ClinicalTrials.gov · Last updated 3 Sept 2026
Brief summary (registry, in English)
This is a multi-center, open-label Phase 1/2 trial evaluating the safety and efficacy of AB-3028 in subjects with metastatic castration resistant prostate cancer (mCRPC).
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 190 (estimated)
- First submitted
- 10 Dec 2025
- Start date
- 9 Jan 2026
- Primary completion date
- 31 May 2029
- Lead sponsor
- Arsenal Biosciences, Inc.
- Diseases
- Prostate cancer
- NCT number
- NCT07285694
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 190
- From 9 Jan 2026 to the primary completion date, 31 May 2029
- 9 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any prior systemic therapy for CRPC within 14 days prior to scheduled protocol required leukapheresis.
Other illness
- Central nervous system (CNS) metastatic disease, leptomeningeal disease, or cord compression.
Other
- Unwillingness to participate in an extended safety monitoring period.
Who the study is looking for
- At least 18 years of age at time of signing informed consent form.
- Histologically confirmed adenocarcinoma of the prostate, meeting all of the following criteria:
- Documented progressive metastatic castration-resistant prostate cancer (mCRPC) based on PCWG3 criteria.
- Prior prostate cancer treatment with at least 1 novel androgen receptor pathway inhibitor (ARPI) therapy.
- PSMA+ by PSMA PET.
- Measurable disease by RECIST 1.1 criteria, or evaluable disease via measurable PSA (≥ 1 ng/mL) per PCWG3 criteria.
- Adequate organ functions.
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (9)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP) Coordinator of this site? Confirm its status | Aurora | United States | Unknown status |
| City of Hope Coordinator of this site? Confirm its status | Duarte | United States | Unknown status |
| The University of Kansas Cancer Center Coordinator of this site? Confirm its status | Fairway | United States | Unknown status |
| University of Iowa and Holden Comprehensive Cancer Center Coordinator of this site? Confirm its status | Iowa City | United States | Unknown status |
| USC / Norris Comprehensive Cancer Center Coordinator of this site? Confirm its status | Los Angeles | United States | Unknown status |
| University of Minnesota Coordinator of this site? Confirm its status | Minneapolis | United States | Unknown status |
| Perlmutter Cancer Center, NYU Langone Health Coordinator of this site? Confirm its status | New York | United States | Unknown status |
| University of California San Francisco Coordinator of this site? Confirm its status | San Francisco | United States | Unknown status |
| Fred Hutchinson Cancer Center Coordinator of this site? Confirm its status | Seattle | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.